STOCK TITAN
  1. Home
  2. News
  3. RHHBY

Roche Hldg - RHHBY STOCK NEWS

Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.

Roche Holding AG (RHHBY) is a global pioneer in biotechnology and diagnostics, driving innovations in personalized healthcare through groundbreaking pharmaceuticals and advanced diagnostic solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, research breakthroughs, and strategic initiatives shaping modern medicine.

Access authoritative information on Roche's financial performance, regulatory milestones, and therapeutic advancements. Our curated news collection includes:

• Earnings reports and investor communications
• FDA/EMA regulatory updates
• Clinical trial results and R&D partnerships
• Diagnostic technology launches
• Strategic acquisitions and collaborations

Bookmark this page for comprehensive tracking of Roche's progress in oncology, immunology, and molecular diagnostics. Stay informed about developments impacting one of healthcare's most influential innovators through verified updates from primary sources.

News

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

Rhea-AI Summary
Genentech announces positive results from Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic/Latinx people with relapsing MS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
clinical trial
-
News

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

Rhea-AI Summary
Roche announces positive long-term results for Vabysmo in retinal vein occlusion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
clinical trial
-
News

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Rhea-AI Summary
Genentech announces positive long-term results for Vabysmo in macular edema due to retinal vein occlusion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
clinical trial
News

Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment

Rhea-AI Summary
Roche presents positive results from RAINBOWFISH study on Evrysdi treatment for babies with pre-symptomatic SMA, meeting primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of treatment. All babies were able to swallow and feed orally. Evrysdi is the only non-invasive SMA therapy approved in over 100 countries with more than 11,000 patients treated globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment

Rhea-AI Summary
Positive results from the RAINBOWFISH study show that 80% of babies treated with Evrysdi were able to sit without support for at least 5 seconds after 1 year of treatment. Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globally. The study also showed that all babies were able to swallow and feed orally, and none required permanent ventilation. Cognitive skills typical of normal child development were observed after 1 year of treatment. Adverse events were not considered treatment-related and there were no deaths or withdrawals. Early treatment for SMA before symptoms appear is valuable in preserving motor neurons.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News

Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

Rhea-AI Summary
Roche will present new data for OCREVUS and fenebrutinib for multiple sclerosis (MS) and ENSPRYNG for neuromyelitis optica spectrum disorder (NMOSD) at the 9th Joint ECTRIMS-ACTRIMS Meeting. OCREVUS shows significant benefit in slowing long-term disability progression and consistent long-term safety profile in MS. Real-world and clinical data demonstrate impact for underrepresented populations. Safety outcomes from more than 6,000 patients across 12 OCREVUS trials support its favorable safety profile over 10 years. ENSPRYNG shows promising results in NMOSD with lower infection rates compared to other treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
News

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD

Rhea-AI Summary
Genentech will present new data for Ocrevus and fenebrutinib for multiple sclerosis (MS) and Enspryng for neuromyelitis optica spectrum disorder (NMOSD) at the 9th Joint ECTRIMS-ACTRIMS Meeting. Ocrevus shows significant benefit in slowing long-term disability progression and has a consistent safety profile. Real-world and clinical data demonstrate the impact of Ocrevus in underrepresented populations. Enspryng shows long-term safety and efficacy in NMOSD. Fenebrutinib demonstrates brain penetration and reduction of new lesion activity in MS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
-
News

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Rhea-AI Summary
Roche and Alnylam's Phase 2 study of zilebesiran meets primary endpoint with a greater than 15 mmHg reduction in systolic blood pressure at three months
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
clinical trial
-
News

FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

Rhea-AI Summary
Genentech's Biologics License Application for crovalimab, a novel anti-C5 recycling monoclonal antibody for the treatment of PNH, has been accepted by the FDA. Crovalimab achieved disease control and was well-tolerated in the Phase III COMMODORE 2 study. It could provide an option for self-administration every four weeks, reducing clinic visits for PNH patients. Crovalimab is being investigated in a broad clinical development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
clinical trial
News

Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare

Rhea-AI Summary
The Economist Impact report commissioned by Roche Diagnostics reveals that integrating digital health technologies into healthcare systems remains challenging, but all countries surveyed have some foundations in place. Data privacy concerns and stakeholder collaboration are key factors for the future of digital health technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
Stock RHHBY logo
Roche Hldg

OTC:RHHBY

RHHBY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RHHBY Stock Data

279.10B
5.12B
0.93%
Drug Manufacturers - General
Healthcare
Link
Switzerland
Basel